PM Jepang Kishida Mengatakan Akan Mundur Bulan Depan, Membuka Jalan Bagi Pemimpin Baru Berita

PM Jepang Kishida Mengatakan Akan Mundur Bulan Depan, Membuka Jalan Bagi Pemimpin Baru

August 14, 2024
(SeaPRwire) - Perdana Menteri Jepang Fumio Kishida, dalam sebuah langkah mengejutkan pada hari Rabu, mengumumkan bahwa dia tidak akan mencalonkan diri dalam pemilihan kepemimpinan partai yang akan datang pada bulan September, membuka jalan bagi munculnya perdana menteri baru.Kishida terpilih sebagai presiden Partai Demokrat Liberal yang berkuasa pada tahun 2021 dan masa jabatannya selama tiga tahun berakhir pada bulan September. Siapa pun yang memenangkan pemungutan suara partai akan menggantikannya sebagai perdana menteri karena LDP mengendalikan kedua majelis parlemen. Wajah baru merupakan kesempatan bagi partai untuk menunjukkan bahwa mereka sedang berubah menjadi lebih baik, dan Kishida mengatakan dia akan mendukung pemimpin baru."Kita perlu menunjukkan dengan jelas LDP yang terlahir kembali," kata Kishida dalam konferensi pers pada hari Rabu. "Untuk menunjukkan LDP yang berubah, langkah pertama yang paling jelas adalah saya mengundurkan diri.""Saya tidak akan mencalonkan diri dalam pemilihan kepemimpinan partai yang akan datang," katanya.Tertekan oleh partainya, Kishida telah mengalami penurunan peringkat dukungan yang telah turun di bawah 20%.Untuk mencapai kebijakan untuk mengatasi situasi sulit di dalam dan luar Jepang, mendapatkan kembali kepercayaan publik terhadap politik sangat penting, kata Kishida. Dia menyerukan calon anggota parlemen partai untuk mengangkat tangan mereka untuk mencalonkan diri sebagai pemimpin dan melakukan debat kebijakan aktif selama kampanye."Setelah pemimpin baru diputuskan, saya berharap dapat melihat semua orang bersatu dan membentuk tim impian untuk mencapai politik yang dapat mendapatkan pemahaman publik," katanya.Kishida mengatakan dia telah merenungkan kemungkinan pengunduran dirinya untuk beberapa waktu tetapi menunggu sampai dia dapat menempatkan kebijakan kuncinya pada jalurnya, termasuk kebijakan energi yang menyerukan kembalinya tenaga nuklir, peningkatan militer secara drastis untuk menangani ancaman keamanan di wilayah tersebut, dan meningkatkan hubungan dengan Korea Selatan, serta reformasi politik.Spekulasi tentang calon potensial telah jatuh pada sejumlah anggota parlemen senior LDP, termasuk Sekretaris Jenderal Partai Toshimitsu Motegi, Menteri Digital Taro Kono, Menteri Keamanan Ekonomi Sanae Takaichi, dan Menteri Luar Negeri Yoko Kamikawa.Pemenang akan menggantikan Kishida sebagai presiden partai, dan akan didukung sebagai perdana menteri baru dalam pemungutan suara parlemen segera setelahnya. Eksekutif LDP diperkirakan akan memutuskan minggu depan tanggal pemilihan partai.Sejak skandal korupsi pecah, Kishida telah mencopot sejumlah menteri Kabinet dan lainnya dari jabatan eksekutif partai, membubarkan faksi-faksi partai yang dikritik sebagai sumber politik uang-untuk-keuntungan, dan memperketat undang-undang kontrol dana politik. Sepuluh orang — anggota parlemen dan ajudan mereka — didakwa pada bulan Januari.Terlepas dari upaya Kishida, dukungan menurun.Kekalahan pemilihan lokal awal tahun ini mengikis pengaruhnya, dan anggota parlemen LDP telah menyuarakan perlunya wajah baru menjelang pemilihan umum berikutnya. Kekalahan besar dalam pemilihan Majelis Metropolitan Tokyo pada bulan Juli juga menambah dorongan tersebut.Skandal ini berpusat pada dana politik yang tidak dilaporkan yang diperoleh melalui tiket yang dijual untuk acara partai. Ini melibatkan lebih dari 80 anggota parlemen LDP, sebagian besar milik faksi partai besar yang sebelumnya dipimpin oleh mantan Perdana Menteri Shinzo Abe yang dibunuh. Pembunuhan itu muncul ke permukaan sebuah skandal tentang hubungan LDP yang sudah berlangsung lama dan berakar dalam dengan Gereja Unifikasi, yang juga dikritik Kishida.Artikel ini disediakan oleh penyedia konten pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberikan jaminan atau pernyataan sehubungan dengan hal tersebut. Sektor: Top Story, Daily News SeaPRwire menyediakan distribusi siaran pers real-time untuk perusahaan dan lembaga, menjangkau lebih dari 6.500 toko media, 86.000 editor dan jurnalis, dan 3,5 juta desktop profesional di 90 negara. SeaPRwire mendukung distribusi siaran pers dalam bahasa Inggris, Korea, Jepang, Arab, Cina Sederhana, Cina Tradisional, Vietnam, Thailand, Indonesia, Melayu, Jerman, Rusia, Prancis, Spanyol, Portugis dan bahasa lainnya.
More

Kess Energy – Kess Energy Chairman Announces Purchase of 200,000 Shares

August 14, 2024
Brasilia, Brazil – August 14, 2024 – (SeaPRwire) – Kess Energy, a leading junior lithium mining company, is pleased to announce that its Chairman, Inato Ramirez, has purchased 200,000 shares of Kess Energy, further demonstrating his confidence in the company’s future growth and its commitment to delivering value to stakeholders. Strengthening Leadership Commitment The purchase of 200,000 shares by Mr. Ramirez serves to reiterate his strong belief in Kess Energy’s strategic direction and the significant potential of its lithium projects. This investment aligns the Chairman’s interests with those of the company’s stakeholders and signals robust confidence in Kess Energy’s long-term prospects. Chairman’s Statement “I am excited about the future of Kess Energy and our role in driving the global transition to sustainable energy,” said Mr. Ramirez. “This personal investment reflects my full confidence in our team, our assets, and our ability to execute our growth strategy. I am committed to ensuring that we continue to deliver exceptional value to our stakeholders.” Company Vision and Growth Strategy Kess Energy is at the forefront of the lithium industry, focusing on sustainable mining practices and innovation in the South American “lithium triangle”. The company’s strategic initiatives include expanding its lithium production capacity, advancing exploration projects, and forging partnerships to support the burgeoning demand for lithium in electric vehicles and renewable energy storage. About Kess Energy Kess Energy is a junior lithium mining company dedicated to meeting the increasing global demand for lithium through responsible and sustainable mining practices that respect and consider the needs of the communities in which its assets are located. With a portfolio of high-quality lithium assets and a commitment to innovation, Kess Energy is well-positioned to play a pivotal role in the energy transition while enabling communities to share in the commercial benefits of its business.. Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations and projections about future events and are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these statements due to various factors. Know more please contact Phone No.: +55 61 4042 9257, or visit our office at: Centro Empresarial Varig SCN QUADRA 04 BL B – Asa Norte, Brasília – DF, 70714-900, Brazil. Media Contact Brand: Kess Energy Contact: Joseph Hera Email: contact@kessenergy.com Website: https://kessenergy.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More
Dr.Friend Puppy, Pameran di Global Pet Show, Sasar Pasar Luar Negeri Bisnis

Dr.Friend Puppy, Pameran di Global Pet Show, Sasar Pasar Luar Negeri

August 14, 2024
(SeaPRwire) - SEOUL, KOREA, 14 Agustus 2024 -- Merek tidur dan kesehatan premium Dr.Friend's produk perawatan tidur hewan peliharaan, Dr.Friend Puppy (dimiliki oleh World Home Doctor Corp.), akan secara aktif menargetkan pasar luar negeri mulai paruh kedua tahun ini. Dr.Friend Puppy akan berpartisipasi dalam SUPER ZOO di Las Vegas, Amerika Serikat dari tanggal 14-16 Agustus untuk secara aktif mempromosikan teknologi tidur & kesehatan unik Dr.Friend. SUPER ZOO adalah salah satu pameran perdagangan industri hewan peliharaan yang paling mapan dan bergengsi di Amerika Utara. Acara ini telah diadakan sejak tahun 1950, dan dianggap sebagai pameran industri hewan peliharaan terbesar di Amerika Utara. Acara ini terus menjadi salah satu pameran yang paling produktif dan dinamis setiap tahunnya. Setelah CES2024 pada bulan Januari dan IHS2024 pada bulan Maret, Dr.Friend Puppy akan berpartisipasi dalam Super Zoo untuk memperkenalkan teknologi perawatan tidur hewan peliharaan yang unik dan filosofi humanisasi hewan peliharaan kepada para pemangku kepentingan industri hewan peliharaan di seluruh dunia. Secara khusus, Dr.Friend Puppy adalah produk perawatan tidur khusus hewan peliharaan yang menggabungkan teknologi perawatan tidur Dr.Friend, seperti teknologi grounding dan teknologi material alami. Ini memiliki keuntungan untuk menyelaraskan karakteristik alami hewan peliharaan yang paling sehat ketika berada di alam dengan karakteristik lingkungan hidup mereka. Teknologi material fungsional alami inti Dr.Friend, seperti wol arang dengan sifat antibakteri dan wol alami, secara optimal seimbang untuk meningkatkan perawatan tidur hewan peliharaan tanpa menggunakan bahan kimia seperti busa memori, sehingga hewan peliharaan dapat merasakan lingkungan tidur yang nyaman dan stabil setiap hari. Selain itu, teknologi anti air yang melapisi lapisan tipis di atas jaringan kain juga diterapkan untuk mencegah kontaminan yang mungkin terjadi karena sifat lingkungan hidup hewan peliharaan dari menembus permukaan kain, membuatnya lebih higienis dan nyaman digunakan. Dengan mengimbangi kelemahan berbagi lingkungan hidup yang sama dengan pemilik, seperti apartemen, grounding hewan peliharaan memungkinkan hewan peliharaan untuk mendapatkan cukup interaksi alami di kenyamanan rumah mereka sendiri. Dr.Friend akan menyoroti berbagai keunikan dan diferensiasi Dr.Friend Puppy, seperti mewujudkan nilai humanisasi hewan peliharaan untuk akhirnya menjaga kesehatan, mencegah berbagai penyakit, dan mengurangi biaya pengobatan. "Teknologi grounding dan material alami Dr.Friend terus mendapatkan kredibilitas ilmiah melalui studi anti-inflamasi dan pereda stres yang telah kami lakukan sejak tahun 2018," kata Kim Ji Youn, CEO Dr.Friend, yang berpartisipasi dalam pameran tersebut. "Secara khusus, makalah efek pereda stres yang diterbitkan dalam Biomedicines, jurnal tingkat SCI, menunjukkan minat tinggi di antara para profesional kesehatan hewan seperti dokter hewan AS." Dia juga mengatakan, "Karena kami sedang mendiskusikan uji klinis dengan organisasi medis dalam dan luar negeri untuk membantu meningkatkan kesehatan hewan peliharaan, kami akan secara aktif mempromosikan keunggulan teknologi perawatan tidur dan prinsip kesehatan kami untuk memperluas peluang kerja sama dengan berbagai pembeli dan mitra." Setelah pameran Super Zoo, Dr.Friend Puppy juga akan berpartisipasi dalam Pet Fair Asia, 21-25 Agustus di Shanghai, Cina, memperluas strategi pertumbuhannya ke wilayah Asia Pasifik. Pet Fair Asia adalah pameran produk hewan peliharaan internasional terbesar di Asia, dan bersama dengan Super Zoo, merupakan salah satu pameran hewan peliharaan terbesar dan paling berpengaruh di dunia. Acara tahun ini akan menjadi yang terbesar sejak pertama kali diadakan pada tahun 1997, dan Dr.Friend akan mempresentasikan nilai dan teknologi tidur & kesehatan otentiknya kepada lebih dari 100.000 pembeli dan pengunjung, menjelajahi peluang untuk memperluas penjualan dan membangun kemitraan strategis. About Dr. Friend Dr. Friend adalah merek tempat tidur fungsional perawatan tidur yang menggabungkan fungsi ergonomis dan material premium. Dibuat melalui penelitian dan pengembangan berkelanjutan untuk jangka waktu yang lama untuk mewujudkan lingkungan tidur yang aman dan stabil dan untuk memuaskan pelanggan setiap saat. Media Contact Brand: Dr.Friend Puppy (World Home Doctor Corp.) Contact : Chon GyeongUn Email: cgu0823@worldhomedr.com Phone: +8210-4981-6360 Website: Artikel ini disediakan oleh penyedia konten pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberikan jaminan atau pernyataan sehubungan dengan hal tersebut. Sektor: Top Story, Daily News SeaPRwire menyediakan distribusi siaran pers real-time untuk perusahaan dan lembaga, menjangkau lebih dari 6.500 toko media, 86.000 editor dan jurnalis, dan 3,5 juta desktop profesional di 90 negara. SeaPRwire mendukung distribusi siaran pers dalam bahasa Inggris, Korea, Jepang, Arab, Cina Sederhana, Cina Tradisional, Vietnam, Thailand, Indonesia, Melayu, Jerman, Rusia, Prancis, Spanyol, Portugis dan bahasa lainnya.
More
Solidton Siap Meluncurkan Ekosistem DeFi dengan Pinjaman P2P, dan Lebih Banyak Fitur Bisnis

Solidton Siap Meluncurkan Ekosistem DeFi dengan Pinjaman P2P, dan Lebih Banyak Fitur

August 14, 2024
(SeaPRwire) - Solidton adalah proyek baru yang akan datang yang menggabungkan keuangan terdesentralisasi (DeFi) dan dunia virtual.Tokyo, Jepang, 14 Agustus 2024 -- Tim senang untuk mengumumkan peluncuran ekosistem DeFi mereka yang akan datang. Platform baru ini akan hadir dengan pinjaman P2P, staking, dan fitur inovatif lainnya. Dengan misi untuk menyatukan orang-orang dalam komunitas kripto, Solidton bertujuan untuk membuat manajemen keuangan dapat diakses oleh semua orang. Proyek ini menawarkan solusi komprehensif dengan instrumen transparan dan aman yang menginspirasi kepercayaan pada pengguna. Dengan struktur tokenomics yang sederhana dan peta jalan yang berwawasan ke depan, Solidton bermaksud untuk mengubah beberapa aspek yang terkait dengan DeFi. Mentransformasikan DeFi dengan Fitur Baru yang Menarik Pada inti proyek Solidton adalah misi untuk mentransformasi dan mendemokratisasi keuangan terdesentralisasi (DeFi). Secara khusus, inilah yang dapat diharapkan pengguna dari solusi DeFi komprehensif ini: Dompet non-kustodial memberi pengguna kendali penuh atas dana mereka dan memungkinkan mereka untuk mengelola token SON dengan aman.Agregator swap mengintegrasikan likuiditas dari berbagai protokol DeFi sehingga pengguna dapat dengan mudah bertukar antar mata uang kripto.Kartu debit DeFi memungkinkan pengguna untuk menghabiskan mata uang kripto mereka dalam situasi sehari-hari.Gerbang pembayaran memungkinkan transaksi instan dan aman pada blockchain TON menggunakan token SON tanpa perantara.Dengan pinjaman P2P, pengguna dapat langsung meminjam atau meminjamkan dana pada blockchain TON tanpa perantara. Pertanian hasil memungkinkan pengguna untuk mendapatkan hadiah dengan memberikan likuiditas ke kumpulan Soliton dalam protokol DeFi.Stablecoin seperti USDC dan USDT tersedia untuk mengurangi volatilitas dan menyimpan nilai dalam blockchain TON. Layanan asuransi terdesentralisasi memungkinkan pengguna untuk membuat dan menggunakan produk asuransi untuk aset mereka tanpa perusahaan tradisional. Keuntungan dari pendekatan ini adalah penghapusan pihak perantara, memberikan transparansi dan otomatisasi.Dompet DeFi adalah cara yang aman untuk mengelola token SON dan berinteraksi dengan dApps pada blockchain TON. Agregator menyederhanakan akses ke protokol DeFi dengan menggabungkan likuiditas dari berbagai sumber. Solidton mengusulkan resepnya untuk mentransformasi DeFi melalui fitur-fitur ini dan membuatnya lebih mudah diakses oleh khalayak yang lebih luas. Singkatnya, ini adalah proyek solusi yang berpusat pada pengguna dan berfokus pada utilitas yang akan segera tersedia untuk penggemar DeFi. Sekilas tentang Solidton Melalui Peta Jalan dan Tokenomics-nya Peta jalan Solidton adalah cara yang baik untuk menilai seberapa serius tim terhadap proyek ini. Dengan empat fase pengembangan, tim memiliki rencana yang jelas untuk mencapai tujuan mereka. Pada Fase 1, tim meluncurkan situs webnya dan merilis whitepaper-nya sementara mendekati penjualan token. Fase 2 berfokus pada mendapatkan listing di bursa utama dan memperkenalkan Solidton Wallet. Fase ketiga melihat integrasi layanan DeFi, peluncuran fitur sosial dan forum, dan pertukaran DEX. Terakhir, di fase 4, tata kelola dan pemungutan suara untuk pemegang token akan diterapkan bersamaan dengan penyelenggaraan acara virtual. Struktur tokenomics proyek juga menunjukkan rencana yang dipikirkan dengan baik. Dengan total 1 miliar token SON, alokasi token akan bekerja sebagai berikut: 64% token akan tersedia selama penjualan token, berjumlah total 640 juta SON.16% akan dialokasikan untuk pengembangan ekosistem, sejumlah 160 juta SON.Tim akan menerima alokasi yang terkunci sebesar 7%, setara dengan 70 juta SON hingga 2026.Mitra dan penasihat akan menerima 4% (atau 40 juta) SON.Cadangan likuiditas dan listing sebesar 9%, berjumlah total 90 juta SON, juga disisihkan. Tentang Solidton Solidton adalah proyek baru yang akan datang yang menggabungkan keuangan terdesentralisasi (DeFi) dan dunia virtual. Tim ini bekerja keras untuk menyediakan platform yang transparan dan aman bagi pengguna. Dengan Solidton, pengguna dapat mengharapkan kejujuran dan penciptaan nilai dalam setiap aspek ekosistem. Tujuan mereka adalah untuk menginspirasi harapan dan kepercayaan dalam komunitas. Dengan kontrak pintar yang diaudit dan tim yang transparan, Solidton mengusulkan platform yang aman dan andal untuk komunitasnya. Fitur proyek saat ini sedang dalam pengembangan, dan tim akan terus memperbarui komunitas tentang setiap kemajuan yang dibuat. Saat peluncuran resmi mendekat, belajar lebih lanjut tentang Solidton melalui dan memungkinkan. Halaman media sosial yang tercantum di bawah ini adalah cara yang baik untuk melacak kemajuan Solidton dari waktu ke waktu. | | | Penafian: Ini adalah siaran pers dan tidak mengandung saran keuangan apa pun. Pembaca harus melakukan riset sendiri sebelum mengambil tindakan apa pun yang terkait dengan perusahaan yang disebutkan. Anda bertanggung jawab penuh, secara langsung atau tidak langsung, atas kerusakan atau kerugian yang disebabkan atau diduga disebabkan oleh atau sehubungan dengan penggunaan atau kepercayaan pada konten, barang, atau layanan apa pun yang disebutkan dalam siaran pers. Cryptocurrency bersifat volatil.Artikel ini disediakan oleh penyedia konten pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberikan jaminan atau pernyataan sehubungan dengan hal tersebut. Sektor: Top Story, Daily News SeaPRwire menyediakan distribusi siaran pers real-time untuk perusahaan dan lembaga, menjangkau lebih dari 6.500 toko media, 86.000 editor dan jurnalis, dan 3,5 juta desktop profesional di 90 negara. SeaPRwire mendukung distribusi siaran pers dalam bahasa Inggris, Korea, Jepang, Arab, Cina Sederhana, Cina Tradisional, Vietnam, Thailand, Indonesia, Melayu, Jerman, Rusia, Prancis, Spanyol, Portugis dan bahasa lainnya. HUBUNGI: Salabaev D. contact at solidton.io
More

Sunrise Records Melonjak 132% dalam Penjualan Semester Pertama, Ditampilkan di Laporan TV Guizhou sebagai Produsen Material Anode Terkemuka

August 14, 2024
(SeaPRwire) - ZIBO, China, 13 Agustus 2024 -- Sunrise New Energy Co., Ltd. (“Sunrise”, the “Company”, “we” or “our”) (NASDAQ: EPOW), hari ini mengumumkan bahwa program "Finance Qianxinan" di Channel Televisi Radio Provinsi Guizhou menampilkan wawancara dengan Bapak Haiping Hu, pendiri dan CEO Sunrise. Laporan tersebut menyoroti bahwa Sunrise adalah produsen terkemuka bahan anoda baterai lithium-ion, mendorong inovasi industri melalui inovasi teknologi dan telah memegang lebih dari 70 paten secara global. Produk Sunrise mencakup berbagai macam bahan anoda, termasuk grafit sintetis, grafit alami, grafit komposit, karbon lunak, karbon keras, dan silikon-karbon, yang banyak digunakan dalam elektronik, kendaraan listrik, dan penyimpanan energi. Sunrise telah membangun kemitraan R&D yang mendalam dengan berbagai perusahaan terkemuka di industri di seluruh rantai nilai. “Pada paruh pertama tahun 2024, Sunrise (Guizhou) New Energy Materials Co., Ltd. telah menjual produk sebanyak 10.400 ton, meningkat 132% dibandingkan periode yang sama tahun lalu.” komentar Bapak Haiping Hu. “Kapasitas produksi Perusahaan dapat memenuhi meningkatnya permintaan bahan anoda kelas atas dari berbagai perusahaan terkemuka yang telah dikontraknya.” Channel Televisi Radio Provinsi Guizhou berkomentar bahwa Sunrise memperkuat peran utama inovasi teknologi dan industrialisasi. Perusahaan terus meningkatkan daya saingnya, secara efektif mendorong pengembangan industri berkualitas tinggi, dan telah memberikan kontribusi positif bagi ekonomi Provinsi Guizhou. Tentang Sunrise New Energy Co., Ltd Berkantor pusat di Zibo, Provinsi Shandong, China, Sunrise New Energy Co., Ltd., melalui perusahaan patungannya, bergerak dalam pembuatan dan penjualan bahan anoda grafit untuk baterai lithium-ion. Perusahaan patungan Perusahaan telah menyelesaikan pembangunan fasilitas manufaktur dengan kapasitas produksi 50.000 ton di Provinsi Guizhou, China. Pabrik ini beroperasi dengan menggunakan listrik murah dari sumber energi terbarukan, yang membantu membuat Sunrise New Energy menjadi produsen bahan anoda grafit berbiaya rendah dan berdampak lingkungan rendah. Bapak Haiping Hu, pendiri dan CEO Perusahaan, adalah seorang pelopor utama untuk industri anoda grafit di China yang dimulai sejak tahun 1999. Tim manajemen Perusahaan juga terdiri dari para ahli dengan pengalaman bertahun-tahun dan rekam jejak keberhasilan yang kuat di industri anoda grafit. Selain itu, Perusahaan juga mengoperasikan platform berbagi pengetahuan di China. Untuk informasi lebih lanjut, silakan kunjungi situs web Perusahaan di . Pernyataan berwawasan ke depan Pernyataan tertentu dalam siaran pers ini mengenai harapan, rencana, dan prospek masa depan Perusahaan merupakan pernyataan berwawasan ke depan sebagaimana didefinisikan oleh Private Securities Litigation Reform Act of 1995. Pernyataan berwawasan ke depan termasuk pernyataan tentang rencana, tujuan, sasaran, strategi, peristiwa mendatang, hasil yang diharapkan, asumsi, dan pernyataan faktual lainnya yang belum terjadi. Setiap kata yang merujuk pada "dapat", "akan", "ingin", "harus", "percaya", "harapkan", "harapkan", "perkirakan", "perkirakan" atau kata-kata non-faktual serupa lainnya, harus dianggap sebagai pernyataan berwawasan ke depan. Karena berbagai faktor, hasil sebenarnya mungkin berbeda secara material dari hasil historis atau isi yang diungkapkan dalam pernyataan berwawasan ke depan ini. Faktor-faktor ini meliputi, tetapi tidak terbatas pada, tujuan strategis perusahaan, rencana masa depan perusahaan, permintaan pasar dan penerimaan pengguna terhadap produk atau layanan perusahaan, pembaruan teknologi, tren ekonomi, reputasi dan merek perusahaan, dampak persaingan industri dan penawaran, kebijakan dan peraturan terkait, pasang surut kondisi makro ekonomi China, kondisi pasar internasional yang relevan, dan risiko dan asumsi terkait lainnya yang diungkapkan dalam Laporan Tahunan Perusahaan pada Formulir 20-F yang diterbitkan di situs web SEC. Mengingat hal di atas dan alasan terkait lainnya, kami mendorong investor untuk mengunjungi situs web SEC dan mempertimbangkan faktor-faktor lain yang mungkin memengaruhi hasil operasional Perusahaan di masa mendatang. Perusahaan tidak berkewajiban untuk mempublikasikan amandemen terhadap perubahan dalam pernyataan berwawasan ke depan ini kecuali diwajibkan oleh hukum. Untuk informasi lebih lanjut, silakan hubungi: Perusahaan: Departemen Hubungan Investor Email: Telepon: +86 4009919228Artikel ini disediakan oleh penyedia konten pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberikan jaminan atau pernyataan sehubungan dengan hal tersebut. Sektor: Top Story, Daily News SeaPRwire menyediakan distribusi siaran pers real-time untuk perusahaan dan lembaga, menjangkau lebih dari 6.500 toko media, 86.000 editor dan jurnalis, dan 3,5 juta desktop profesional di 90 negara. SeaPRwire mendukung distribusi siaran pers dalam bahasa Inggris, Korea, Jepang, Arab, Cina Sederhana, Cina Tradisional, Vietnam, Thailand, Indonesia, Melayu, Jerman, Rusia, Prancis, Spanyol, Portugis dan bahasa lainnya.
More
Dr.Friend Puppy, Exhibits at Global Pet Show, Targeting Overseas Markets SeaPRwire

Dr.Friend Puppy, Exhibits at Global Pet Show, Targeting Overseas Markets

August 14, 2024
Seoul, Korea – August 14, 2024 – (SeaPRwire) -The premium sleep and healthcare brand Dr.Friend’s pet sleep care product, Dr.Friend Puppy (owned by World Home Doctor Corp.), will be actively targeting overseas markets from the second half of the year. Dr.Friend Puppy will participate in the SUPER ZOO in Las Vegas, USA from August 14-16 to actively promote Dr.Friend’s unique sleep & healthcare technology. SUPER ZOO is one of the most established and prestigious pet industry trade shows in North America. It has been held since 1950, and it is considered the largest pet industry show in North America. It continues to be one of the most productive and vibrant shows yearly. Following CES2024 in January and IHS2024 in March, Dr.Friend Puppy will participate in Super Zoo to introduce its unique pet sleep care technology and pet humanization philosophy to pet industry stakeholders around the world. In particular, Dr.Friend Puppy is a pet-specific sleep care product that incorporates Dr.Friend’s sleep care technology, such as grounding technology and natural material technology. This has the advantage of harmonizing the natural characteristics of pets that are healthiest when they are in nature with the characteristics of their living environment. Dr.Friend’s core natural functional material technologies, such as charcoal wool with antibacterial properties and natural wool, are optimally proportioned to enhance pet sleep care without using chemicals such as memory foam, so pets can feel comfortable and stable sleeping environments every day. In addition, a water-repellent technology that coats a thin film on top of the fabric tissue is also applied to prevent contaminants that may occur due to the nature of the pet’s living environment from penetrating the surface of the fabric, making it more hygienic and convenient to use. By compensating for the disadvantage of sharing the same living environment as the owner, such as an apartment, pet grounding allows pets to get enough natural interaction in the comfort of their home. Dr.Friend will highlight various uniqueness and differentiation of Dr.Friend Puppy, such as realizing the value of pet humanization to ultimately maintain health, prevent various diseases, and reduce medical costs. “Dr.Friend’s grounding and natural material technology continues to gain scientific credibility through anti-inflammatory and stress relief studies that we have been conducting since 2018,” said Kim Ji Youn, CEO of Dr.Friend, who is participating in the exhibition. “In particular, the stress relief effect paper published in Biomedicines, an SCI-level journal, is showing high interest among animal healthcare professionals such as US veterinarians.” She also said, “As we are currently discussing clinical trials with domestic and foreign medical organizations to help improve pets’ health, we will actively promote the advantages of our sleep care technology and healthcare principles to expand cooperation opportunities with various buyers and partners.” After the Super Zoo exhibition, Dr.Friend Puppy will also participate in Pet Fair Asia, August 21-25 in Shanghai, China, expanding its growth strategy to the Asia Pacific region. Pet Fair Asia is Asia’s largest international pet products exhibition, and along with the Super Zoo, it is one of the world’s largest and most influential pet shows. This year’s event will be the largest since its inception in 1997, and Dr.Friend will present its authentic sleep &healthcare value and technology to more than 100,000 buyers and visitors, exploring opportunities to expand sales and establish strategic partnerships. About Dr. Friend Dr. Friend is a sleep care functional bedding brand that combines ergonomic functions and premium materials. It was created through continuous research and development for a long period of time to realize a safe and stable sleeping environment and to satisfy customers at all times. Media Contact Brand: Dr.Friend Puppy (World Home Doctor Corp.) Contact : Chon GyeongUn Email: cgu0823@worldhomedr.com Phone: +8210-4981-6360 Website: https://worldhome.global/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More
C14 Enters into Partnership with Tune.FM SeaPRwire

C14 Enters into Partnership with Tune.FM

August 14, 2024
New York, NY – August 14, 2024 – (SeaPRwire) – C14, a leading provider of fiat-to-crypto on and off-ramp solutions, has joined forces with Tune.FM, a cutting-edge music NFT trading platform, to release an off-ramp solution for JAM, the native token of the Tune.fm application. This collaboration marks a significant step forward in the integration of cryptocurrency with the music industry, providing users with seamless conversion of JAM tokens to fiat currency. Tune.fm is a revolutionary platform where artists and fans can trade music NFTs, unlocking new revenue streams and interactive experiences in the music ecosystem. The native token, JAM, is at the heart of Tune.fm’s economy, facilitating transactions and rewarding artists and fans alike. With the introduction of an off-ramp solution, users will now have the ability to convert JAM tokens into fiat currency, enhancing the platform’s usability and accessibility. This partnership deepens C14 and Tune.fm’s existing relationship, where C14 provides on-ramping services for Tune.fm’s existing base of over TK users. C14 provides ramping services for JAM for users in over two dozen countries. JAM is built on the Hedera Hashgraph, a low cost, high throughput distributed ledger technology. C14 has established itself as a trusted partner in the crypto space, offering robust solutions that bridge the traditional financial system with the digital asset world. The off-ramp for JAM tokens leverages C14’s secure and efficient infrastructure, ensuring a smooth and reliable conversion process. C14 and Tune.FM will roll out service for users in the United States versus ACH first, with instant SEPA payouts to the European Union following soon after. Key Benefits of the Collaboration Seamless Conversion: Users can easily convert their JAM tokens into fiat currency, broadening the utility and acceptance of JAM in the real world. Enhanced Accessibility: The off-ramp solution lowers the barriers for new users to engage with Tune.FM, providing a straightforward method to cash out their JAM tokens. Security and Trust: C14’s proven track record in the industry ensures a safe and compliant process for all transactions, instilling confidence in users. “Partnering with Tune.fm aligns perfectly with our mission to make crypto accessible to everyone,” said Erich Grant, CEO of C14. “We are excited to support the vibrant community of artists and fans on Tune.fm by providing an easy and secure way to convert JAM tokens to fiat currency.” “This collaboration with C14 is a game-changer for our platform,” added Andrew Antar, CEO of Tune.FM. “The off-ramp solution not only enhances the user experience but also paves the way for wider adoption of JAM tokens in the mainstream economy.” The off-ramp for JAM tokens is expected to be available to Tune.FM users starting July 25th For more information on how to use the off-ramp, visit Tune.FM. About C14 C14 is a leading provider of fiat-to-crypto on and off-ramp solutions, dedicated to bridging the gap between traditional finance and the digital asset economy. With a focus on security, compliance, and user experience, C14 offers seamless conversion services that empower users to interact with the crypto world effortlessly. To know more please contact +1 (845) 366-6902. About Tune.FM Tune.fm is a pioneering music NFT trading platform that empowers artists and fans to engage in a vibrant digital music economy. By leveraging blockchain technology and the JAM token, Tune.FM enables transparent and rewarding interactions within the music industry, fostering a new era of music ownership and distribution. Media Contacts Erich Grant, Founder of C14 erich@c14.money Website: https://c14.money/ Andrew Antar, Founder of Tune.FM hello@Tune.FM Website: http://tune.fm/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More

Experience Eternal Romance with Exquisite Blue Diamonds

August 14, 2024
SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection - Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your gentleness is my greatest safeguard in this life. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection - Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection - Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6992 2589Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Valuufy Established to Transform Sustainable Business and Investing JCN Newswire

Valuufy Established to Transform Sustainable Business and Investing

August 14, 2024
KYOTO, JAPAN, Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Valuufy, a pioneering fintech startup drawn from a decades’ work in measuring and creating sustainable value at Doshisha University’s Value Research Center, has launched with its groundbreaking ValuuCompass, a comprehensive framework set to transform sustainable business practices and sustainability investing by providing a fully transparent and actionable framework for assessing and improving sustainability performance.The current state of sustainability reporting:· Confusing and inefficient for companies· Multiple different standards and metric· Emphasis on past activities rather than future strategies· Difficult to capture real impacts on people and the environment· No reliable benchmark for investors to assess sustainability risks and opportunitiesValuuCompass addresses precisely these challenges.The ValuuCompass addresses a critical gap in the market: the lack of a holistic, transparent system for assessing a company's true stakeholder impacts and sustainability risks that arise from these. At the heart of this new product is the Value Model, which has synthesized more than 1,200 individual impact measurements from leading global ESG and sustainability frameworks into a clear goal-based model to measure stakeholder impacts and value creation. With this new assessment system, Valuufy offers businesses and investors a clear, actionable view of value creation that goes far beyond traditional sustainability and ESG metrics. "In an era where 'value washing' - the pretence of sustainable value creation - poses significant financial and reputational risks, both companies and investors need a reliable compass," said Kyle Barnes, CEO of Valuufy. "Valuufy's products and services provide these capabilities, offering a level of transparency and insight that goes beyond all other existing solutions."Dr. Philip Sugai, Director of Research at Valuufy and Director at the Value Research Center, emphasized the revolutionary approach that Valuufy is taking: "The current systems underlying sustainability and ESG are fundamentally broken, focusing on backwards-looking disclosures rather than forward-looking strategies. Valuufy was established to change this paradigm, helping businesses to shift their focus to creating real, and measurable value across their key stakeholders."Valuufy’s ongoing activities aim to bring this important mindset to business strategy creation for businesses of all sizes. "Today, we're not just launching a new tool; we're setting a new standard for sustainable business and investing," added Marco Koeder, Chief Marketing Officer. By 2030, we aim to establish the Value Model as the global benchmark for measuring and creating sustainable value."Benefits of ValuuCompass for Companies:· First universal, objective standard to measure real impact on people and the planet· Provides actionable recommendations for improvement· Enhances performance in the sustainability reporting framework· Transforms complex data into clear, strategic insightsBenefits of ValuuCompass for Investors:· Enables truly informed decisions on sustainability risks and opportunities· Offers rigorous, quantifiable metrics for portfolio assessment· Aligns perfectly with the financial sector's data-driven approach· Provides a competitive edge in sustainable investingDiscover how Valuufy is revolutionizing the future of sustainability at www.valuufy.com.About ValuufyValuufy Inc seeks to transform how the world understands and acts on sustainability. Founded in 2024, Valuufy is a registered Japanese startup in Kyoto, Japan, born of 10 years of academic value research at Doshisha University and the Value Research Center. Led by an international team with expertise in value research, sustainability strategies, innovative technologies, business development, and ESG assessments, Valuufy provides a suite of products and services to promote value-creation activities across stakeholders for businesses of all sizes - to set new standards in transparent, data-driven decision-making in the realm of sustainability and value creation. For more, visit www.valuufy.com.The Value Research Center was officially established at Doshisha University in Kyoto, Japan, in November 2021 to develop a system for measuring, monitoring, assessing, and reporting on organizations' value creation and destruction impacts on various stakeholder groups. The result is the Value Model, which forms the foundation for ValuuCompass.Contact:Press/MediaE: news@valuufy.comT: +81-90-9742-0860Marco KoederE: marco@valuufy.com T: +49-175-999-8647 Copyright 2024 JCN Newswire via SeaPRwire.com.
More
“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates JCN Newswire

“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates

August 14, 2024
TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved in the U.S., Japan, China, South Korea, Hong Kong, and Israel, and is being marketed in the U.S., Japan, and China.LEQEMBI’s approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.(1),(2) In the UAE, it is reported that 4.09% of those over 60 years old have dementia.(3) AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.(4)Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Biogen will commercialize LEQEMBI in the UAE.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(5) Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(6) About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with LEQEMBI and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P
More

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results

August 14, 2024
Development Highlights- During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs.- In the first half of 2024, the Group's revenue from innovative products reached RMB 6.13 billion, a year-on-year increase of 14.8%. In addition to innovative products, the Group has 11 generic drugs approved by the NMPA for market launch. The overall revenue of generic drugs achieved positive growth in the first half of 2024. New products are an important driver of the Group’s revenue growth. In the first half of 2024, the Group’s revenue from new products launched within five years reached RMB 6.03 billion, representing a year-on-year increase of 39.6%.- As of 30 June 2024, the Group had a total of 43 innovative drug candidates in the field of oncology, 8 innovative drug candidates related to the respiratory system, 6 innovative drug candidates related to liver disease, and 4 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 3 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 5 innovative oncology drug candidates, 1 innovative respiratory system drug candidate, 1 innovative liver disease drug candidate, and 1 innovative surgery/analgesia drug candidates are in Phase III clinical trials. In addition, the Group had a total of 18 biosimilar or generic drug oncology candidates, 3 additional biosimilar or generic liver disease drug candidates, 21 biosimilar or generic respiratory system drug candidates, and 10 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. In February and July 2024, for anlotinib in combination with benmelstobart, two marketing applications were submitted to the Center for Drug Evaluation (“CDE”) of NMPA for the treatment of second- and third-line endometrial cancer, and first line renal cell carcinoma, respectively. In July 2024, the Phase III clinical study of anlotinib in combination with chemotherapy for the first-line treatment of advanced soft tissue sarcoma achieved positive results. The Group has submitted the marketing application and received acceptance for the new indication.- Yilishu (Efbemalenograstim Alfa Injection) was approved in May 2023 for the prevention and treatment of neutropenia in cancer patients taking chemotherapy drugs. In December 2023, Efbemalenograstim alfa was successfully included in the National Reimbursement Drug List (“NRDL”), and its sales volume accelerated in the first half of 2024, becoming an important contributor to the Group’s revenue growth.- Andewei (Benmelstobart Injection) is a humanized PD-L1 monoclonal antibody that was approved by the NMPA in April 2024 for use in combination with anlotinib, carboplatin, and etoposide in the first-line treatment of extensive-stage small cell lung cancer.- Anboni (Unecritinib Fumarate Capsules) is a small molecule inhibitor of tyrosine kinase ROS1/ALK/c-Met, which was approved by the NMPA in April 2024 for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer. It is the first domestically produced targeted drug approved for the treatment of ROS1-positive non-small cell lung cancer.- The clinical trial application of Lanifibranor was submitted to and accepted by CDE in March 2023. In July, Lanifibranor was included in the list of breakthrough therapeutics. Currently, Lanifibranor is conducting Phase III clinical trials globally and is actively advancing the enrollment of subjects. Lanifibranor is China's first oral MASH drug to enter Phase III clinical trials and is expected to fill the gap in China's MASH market.HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the “Period”).During the Period, the Group recorded revenue of approximately RMB15.87 billion, a year-on-year increase of approximately 11.1%. Profit attributable to owners of the parent company was approximately RMB3.02 billion, a year-on-year increase of approximately 139.7%. Earnings per share attributable to owners of the parent company were approximately RMB16.39 cents. The significant year-over-year increase in profit attributable to owners of the parent company was mainly due to the gain on disposal of subsidiaries under discontinued operations during the current Period. Adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB1.54 billion, a YOY increase of approximately 14.0%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB8.55 billion, bank deposits classified as non-current assets of approximately RMB9.18 billion, and wealth management products of approximately RMB4.61 billion in total, and total fund reserves amounting to approximately RMB22.34 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK3 cents per share (1H2023: HK2 cents).Miss Tse, Theresa Y Y, Executive Director and ChairwomanSales: Entering harvesting of innovative results period and sales revenue from generic products further risesAlways placing utmost importance on research and development (“R&D”), the Group leverages in-depth research and development to achieve significant benefits. At present, the Group has entered the harvest period of its innovative development, driving further growth in sales revenue. During the Period, sales of oncology drugs increased by 19.5% year-on-year to approximately RMB5.36 billion, accounting for approximately 33.8% of the Group's revenue. Sales of surgical/analgesic medications increased by 29.9% year-on-year to approximately RMB2.58 billion, accounting for approximately 16.3% of the Group's revenue. Sales of liver disease drugs amounted to approximately RMB2.03 billion, accounting for approximately 12.8% of the Group's revenue. In addition, the sales contributions of products in various areas such as respiratory system, cardio-cerebral vascular medicines, and others increased simultaneously, accounting for approximately 11.2%, 8.6%, and 17.3% of the Group's total revenue, respectively.In the field of respiratory system, The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the volume-based procurement (VBP), enabling Tianqing Suchang’s sales to achieve steady growth during the Period. In the meanwhile, the Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly during the Period.In the field of surgery/analgesia, the Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth during the Period.Mr. Tse, Eric S Y, Executive Director and Chief Executive OfficerR&D: R&D as the core for driving the Group's continuous innovation and developmentThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver disease, respiratory system and surgery/analgesia. As at the end of the reporting Period, the Group had 76 innovative products in development, including 46 oncology products, 6 liver disease products, 9 respiratory system products, 5 surgery/analgesia products, and 10 other products. In addition, the Group had 65 generic drug products in development.The Group has always put R&D at its core, and has continuously improved its R&D capabilities and speed by embracing the R&D concept of combining independent innovation, collaborative development, and the development of both innovative and generic drugs. It considers R&D as the foundation of its sustainable development. In the first half of 2024, it incurred R&D expenses of approximately RMB 2.58 billion, accounting for approximately 16.2% of the Group’s revenue. It is expected that the number of innovative products launched to the market will reach 25 by 2026. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for long-term sustainable growth.Sino Biopharmaceutical ManagementProspects: Keep up with national development strategy and accelerate globalization processThe pharmaceutical industry has become one of the fastest growing and most promising fields in China and even the world. As the world’s second largest pharmaceutical market, China’s demand for medical and healthcare products has grown rapidly in recent years, with breakthroughs being made in biotechnology. Innovation has become a new driving force for the high-quality development of China’s pharmaceutical industry. The Group has been closely monitoring the development of the country, society and the industry, and has continuously optimized its development strategy. Under the four main strategies of “organizational integration, comprehensive innovation, internationalization, and digitalization”, the Group will actively innovate its organizational structure, comprehensively improve its operational efficiency, focus on the innovation and development of the four main therapeutic areas of oncology, liver disease, respiratory system, and surgery/analgesia, and actively accelerate the global deployment of its business.The Group is committed to its mission of becoming a “leading global pharmaceutical company through delivering innovative therapies for patients”. It strives to promote innovative development through its dual engines of internal R&D and business development. Over the years, the Group has stepped up its R&D investment and built strong internal R&D capabilities. At the same time, it has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises. In April 2024, the Group entered into a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the Mainland Chinese market. This move not only demonstrates The Group's innovative strength in the pharmaceutical field, but also reflects its far-reaching influence in international cooperation.Looking ahead, The Group will adhere to its dual-pronged approach in the implementation of its globalization strategy. Through this approach, the Group will bring global pharmaceutical innovations to China to benefit Chinese patients, and also go global and open up new markets to accelerate the satisfaction of unmet clinical needs worldwide. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Pilot Tewas Setelah Helikopternya Jatuh di Atap Hotel Australia Selama Penerbangan Tanpa Izin Berita

Pilot Tewas Setelah Helikopternya Jatuh di Atap Hotel Australia Selama Penerbangan Tanpa Izin

August 14, 2024
(SeaPRwire) - Seorang pilot helikopter tewas dan lainnya terluka pada Senin dini hari setelah pilot tersebut menjatuhkan helikopter di atap sebuah hotel di Australia selama penerbangan yang tidak sah, kata pihak berwenang. The New Zealand Herald mengidentifikasi pilot tersebut sebagai Blake Wilson, 23 tahun, dari . Perusahaan penerbangan Nautilus Aviation mengkonfirmasi kepada media bahwa Wilson adalah salah satu karyawan mereka, tetapi belum pernah terbang di Australia sebelumnya. Perusahaan mengatakan bahwa dia adalah anggota kru darat mereka dan memegang lisensi pilot helikopter di Selandia Baru, tetapi tidak diizinkan menerbangkan helikopter perusahaan di Australia. Pria tersebut telah bekerja di Nautilus Aviation selama empat bulan dan baru-baru ini dipromosikan ke pekerjaan kru darat di basis perusahaan lainnya, kata Nautilus Aviation. Sebelum , pria tersebut telah menghadiri acara sosial bersama rekan kerja untuk menandai kepergiannya ke posisi baru, kata perusahaan. Penerbangan tersebut tidak sah dan helikopter "dicuri," tambah perusahaan.Kecelakaan pada Senin pagi dini hari mengakibatkan evakuasi ratusan orang dari gedung tersebut karena api menjilati pesawat.Sebuah pasangan yang menginap di hotel dilarikan ke rumah sakit karena menghirup asap, dan keduanya telah dipulangkan, kata Kepala Superintendent Shane Holmes, yang bertindak sebagai kepala layanan, kepada wartawan. Tidak ada orang lain di darat yang terluka.CEO Bandara Cairns Richard Barker mengatakan temuan awal dari tinjauan pada Senin menunjukkan "tidak ada kompromi pada program atau proses keamanan bandara."Bandara beroperasi di bawah "program keamanan transportasi bertingkat yang disetujui secara federal," kata Barker.Kecelakaan tersebut terjadi di distrik wisata yang ramai di Cairns, sebuah kota tropis dengan 150.000 penduduk di Queensland bagian utara, di mana ini adalah musim puncak bagi wisatawan. Saksi mata mengatakan kepada media lokal bahwa kecelakaan itu terdengar seperti bom meledak.Asap mengepul dan api membubung dari atap DoubleTree Hilton, dan salah satu baling-baling helikopter jatuh ke kolam renang hotel, lapor penyiar Australia ABC.Hotel tersebut tetap dijaga ketat sementara integritas strukturnya sedang diperiksa. Digital telah menghubungi Nautilus Aviation dan polisi Queensland untuk mendapatkan pembaruan. Artikel ini disediakan oleh penyedia konten pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberikan jaminan atau pernyataan sehubungan dengan hal tersebut. Sektor: Top Story, Daily News SeaPRwire menyediakan distribusi siaran pers real-time untuk perusahaan dan lembaga, menjangkau lebih dari 6.500 toko media, 86.000 editor dan jurnalis, dan 3,5 juta desktop profesional di 90 negara. SeaPRwire mendukung distribusi siaran pers dalam bahasa Inggris, Korea, Jepang, Arab, Cina Sederhana, Cina Tradisional, Vietnam, Thailand, Indonesia, Melayu, Jerman, Rusia, Prancis, Spanyol, Portugis dan bahasa lainnya.
More